Tissue plasminogen activator: beyond thrombolysis.
Benarroch
Eduardo E
EE
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. benarroch.eduardo@mayo.edu
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism* / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000378:metabolism*; D020271:Heredodegenerative Disorders, Nervous System / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D006801:Humans; D009473:Neuronal Plasticity / Q000502:physiology; D009479:Neuropeptides / Q000494:pharmacology / Q000502:physiology*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D015843:Serpins / Q000494:pharmacology / Q000502:physiology*; D020521:Stroke / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D009435:Synaptic Transmission / Q000502:physiology; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000097522:Neuroserpin
D005343:Fibrinolytic Agents; D009479:Neuropeptides; D017395:Plasminogen Activator Inhibitor 1; D015843:Serpins; D010959:Tissue Plasminogen Activator; D000097522:Neuroserpin